clinical trial · NCT06299540
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Janssen Cilag S.A.S.·—·recruiting·n = 180
Leukemia, Lymphocytic, Chronic, B-CellIndividual Physical Activity Intervention (IPAI)Ibrutinib
brief summary
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).
started
May 27, 2024
primary completion
Sep 30, 2026
completion
Nov 30, 2027
last updated
Sep 25, 2026
official title
Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol